Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Gastrohep|June 21, 2021
Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?Anna Licata, Maria Giovanna Minissale, Marco Distefano, et al.
Current Medicinal Chemistry|March 29, 2018
Liver and Statins: A Critical Appraisal of the EvidenceAnna Licata, Antonina Giammanco, Maria Giovanna Minissale, et al.
Biomed Research International|August 20, 2013
Metabolic factors and chronic hepatitis C: a complex interplayFabio Salvatore Macaluso, Marcello Maida, Maria Giovanna Minissale, et al.
Frontiers in Pharmacology|August 29, 2022
N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive ReviewAnna Licata, Maria Giovanna Minissale, Simona Stankevičiūtė, et al.
Internal and Emergency Medicine|April 28, 2021
Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohortAnna Licata, Maria Giovanna Minissale, Lydia Giannitrapani, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 2014
The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patientsSalvatore Petta, Stefania Grimaudo, Claudio Tripodo, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 29, 2025
Point-of-Care Testing and Treatment of Hepatitis C Virus in Prisons: The SINTESI Project in SicilyLorenza Di Marco, Fabio Cartabellotta, Fabio Santangelo, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2018
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective studyGiuseppina Novo, Francesca Macaione, Lydia Giannitrapani, et al.
Biomed Research International|March 19, 2020
The Changing Epidemiology of Hepatocellular Carcinoma : Experience of a Single CenterLydia Giannitrapani, Maddalena Zerbo, Simona Amodeo, et al.
Journal of Crohn'S & Colitis|October 13, 2025
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.
Pageof 2